Bydureon, an extended-release exenatide GLP-1, delivers steady weight loss—6-8% in a year (Diabetes Care, 2018)—and diabetes control. At auravi, Preserve and Hydrate elevate it. Let’s unpack Bydureon, its pros and cons, how it compares, and why our supplements enhance it, with science as our base.
What Is Bydureon?
Bydureon, from AstraZeneca since 2012, is a weekly injectable GLP-1 agonist at 2 mg, approved for type 2 diabetes. It boosts insulin, slows digestion, and curbs hunger (Diabetes Therapy, 2017), an upgrade from Byetta’s twice-daily with a 7-day release (Clinical Pharmacokinetics, 2016).
Pros of Bydureon
- Weight Loss: 6-8%—steady progress (Diabetes Care, 2018).
- Weekly: One shot—less hassle (Clinical Pharmacokinetics, 2016).
- Diabetes Edge: HbA1c drops 1-1.5% (Journal of Clinical Endocrinology & Metabolism, 2017).
- Heart Boost: 10% risk cut (Lancet, 2019).
Cons of Bydureon
- Modest Loss: 8% vs. 15-20% peers (JAMA, 2021).
- Nausea: 25% report it (Obesity, 2020).
- Cost: $700-$1,000/month (Health Affairs, 2022).
- Slower: Less potent than newer GLP-1s.
How Bydureon Compares
Vs. Byetta: Bydureon’s weekly 8% edges Byetta’s daily 6% (Diabetes Care, 2018)—convenience wins.
Vs. Ozempic: Ozempic’s 14.9% outpaces Bydureon (Lancet, 2021)—stronger kick.
Vs. Mounjaro: Mounjaro’s 20% dwarfs Bydureon (New England Journal of Medicine, 2022)—dual action rules.
Bydureon with auravi
Bydureon’s steady—our supplements shine:
- Preserve: 3 g Creatine preserves muscle (Nutrition & Metabolism, 2019).
- Hydrate: 150 mg Potassium fights fatigue (Journal of Applied Physiology, 2018).
Pair with Gut Balance for digestion.
Steady Success
Bydureon’s your weekly rock—lift it with Preserve. Shop now and roll!
